Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 464 participants.

Also called NCT02313584

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 464 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02313584
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02313584. Randomized; no masking; primary purpose prevention. Start 2014-12 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
Condition
Thromboembolism
Intervention (Drug)
dabigatran
Intervention (Drug)
placebo
Lead sponsor
Korea University (class: other)

Record details

Record id
cardio:ct-nct02313584
Content hash
c6f8538bab5998b0adc80d3fe3ed5a1cc17870654b179dd70651b3d857b1ef57